The small-molecule drug developer raised equity funding in an Alexandria Venture Investments-backed round.
US-based biopharmaceutical company Skyhawk Therapeutics has completed a $40m funding round featuring Alexandria Venture Investments, the venture capital arm of life sciences real estate investment trust Alexandria Real Estate Equities.
GreatPoint Ventures, ShangPharma Innovation and Agent Capital also participated in the round, along with private investors Tim Disney and the Duke of Bedford, and family investment firms including the Reilly Family.
Skyhawk is developing small-molecule drug therapies intended to treat neurological, oncological and immunological diseases by correcting RNA expression in…
